Key Highlights

  • Net loss for the third quarter widened to USD 42.7 million, or USD 0.73 per share, from USD 24.6 million, or USD 0.54, in the third quarter of 2025, with no Revenue in either period.
  • Operating expenses reached USD 44.7 million versus USD 20.3 million a year earlier, as Research and Development rose 45% to USD 29.6 million and general and administrative expense jumped 155% to USD 15.1 million.
  • Cash, cash equivalents, restricted cash and marketable securities totaled about USD 198.5 million on September 30, 2026, down from about USD 318.1 million at the end of 2025.
  • The FDA target action date for deramiocel in Duchenne muscular dystrophy is November 22, 2026, after an advisory committee voted 9 against and 3 in favor on cardiomyopathy evidence in July.

Pre-Launch Spending Pushes the Quarterly Loss to USD 42.7 Million

Capricor Therapeutics (NASDAQ:CAPR) filed its Quarterly Report on November 10, 2026 and held its call the same day. The biotechnology company develops cell and exosome-based therapies for Duchenne muscular dystrophy, a rare disease that causes progressive muscle loss. It recorded no revenue and a third-quarter net loss of USD 42.7 million, against USD 24.6 million a year earlier. Nine-month net loss was USD 117.3 million, or USD 2.03 per share, versus USD 74.9 million, or USD 1.64. Management said the rise reflects pre-commercial work and Manufacturing scale-up. The filing shows Facility expense within general and administrative costs of USD 2.9 million compared with USD 0.2 million.

November 22 Decision on Deramiocel Follows a Divided Panel

The FDA review of the Biologics license application for deramiocel carries a target action date of November 22, 2026, after the agency treated an August amendment as major and extended the date by three months. On July 29, 2026 an advisory committee voted 3 in favor and 9 against on whether evidence showed effectiveness for cardiomyopathy. The vote is advisory only. The company is now seeking a refined indication for upper limb Impairment in patients older than 9. The Phase 3 HOPE-3 trial met its primary endpoint on upper limb function with a p-value of 0.029. In July the FDA also issued a Form 483 with one observation on trial documentation, and the company said it awaits agency feedback.

Cash Burn, Lease Liabilities and a Legal Dispute Frame the Risk

Cash used in Operating Activities was USD 96.4 million for the nine months, up from USD 46.2 million. Total liabilities were about USD 120.6 million, including USD 92.2 million of leases. Management said it believes cash is enough for at least the next 12 months, and it noted no shares were sold under its at-the-market program this year. It cut its workforce by about 10% in the third quarter and slowed work not tied to deramiocel. The company is also in a contract dispute with Nippon Shinyaku and NS Pharma over its Japan distribution agreement, with arbitration expected to begin in mid-2027. The filing warns that the FDA may request further information at any time.

Where Things Stand

Probably yes for the next 12 months, according to management, but the cash does not remove the regulatory risk. Capricor Therapeutics (NASDAQ:CAPR) held about USD 198.5 million after burning USD 96.4 million in operations over nine months, and it is trimming costs while waiting on the FDA. The November 22 decision is the key event: it will shape launch spending, manufacturing expansion planned for the first half of 2027 and any need to raise capital. The advisory vote and the Form 483 observation remain open questions in the review.